-
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Expert opinion on drug metabolism & toxicology 20121101
-
Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).
The Analyst 20120807
-
Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
Annals of internal medicine 20120619
-
Role of M2 and M3 muscarinic acetylcholine receptor subtypes in activation of bladder afferent pathways in spinal cord injured rats.
Urology 20120501
-
Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors.
The Journal of pharmacology and experimental therapeutics 20111201
-
Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Urology 20111201
-
Time-to-effect with darifenacin in overactive bladder: a pooled analysis.
International urogynecology journal 20111201
-
Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Neurourology and urodynamics 20111101
-
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
British journal of clinical pharmacology 20110801
-
Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.
Journal of the American Geriatrics Society 20110301
-
Patient experience with darifenacin - results of a short-term community-based survey in managing overactive bladder.
Current medical research and opinion 20110201
-
Activation state of the M3 muscarinic acetylcholine receptor modulates mammalian odorant receptor signaling.
Science signaling 20110111
-
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.
Digestive diseases and sciences 20110101
-
Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
Neurourology and urodynamics 20110101
-
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Urology 20101001
-
Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Life sciences 20100731
-
Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.
American journal of physiology. Gastrointestinal and liver physiology 20100701
-
Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors.
American journal of physiology. Gastrointestinal and liver physiology 20100401
-
Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.
American journal of physiology. Gastrointestinal and liver physiology 20091201
-
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.
International urogynecology journal and pelvic floor dysfunction 20091101
-
Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
BJU international 20091001
-
Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice.
British journal of pharmacology 20090401
-
Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
The Journal of pharmacology and experimental therapeutics 20090301
-
In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
British journal of pharmacology 20090301
-
Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Neurourology and urodynamics 20090101
-
Use of antimuscarinics in the elderly.
TheScientificWorldJournal 20090101
-
Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
Journal of cardiovascular pharmacology and therapeutics 20081201
-
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
International journal of clinical practice 20081101
-
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
International journal of clinical practice 20081101
-
Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.
International urogynecology journal and pelvic floor dysfunction 20081001
-
Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.
Clinical interventions in aging 20080901
-
Interstitial granulomatous dermatitis associated with darifenacin.
Journal of drugs in dermatology : JDD 20080901
-
Clinical relevance of health-related quality of life outcomes with darifenacin.
BJU international 20080701
-
Activated cholinergic signaling provides a target in squamous cell lung carcinoma.
Cancer research 20080615
-
A journey to continence: a case study of overactive bladder syndrome.
Urologic nursing 20080601
-
A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.
International journal of clinical practice 20080401
-
The effect of darifenacin on overactive bladders in female and male rabbits.
International urology and nephrology 20080101
-
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Neurourology and urodynamics 20080101
-
Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
Current medical research and opinion 20071101
-
Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.
European journal of pharmacology 20071031
-
Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
Current medical research and opinion 20071001
-
[The recommendations of the Polish Gynecologic Society regarding the use of darifenacin, selective muscarinic antagonists in the treatment of overactive bladder].
Ginekologia polska 20071001
-
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
European urology 20070901
-
Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
European urology 20070901
-
Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
European urology 20070901
-
Cholinergic activation of phasic activity in the isolated bladder: possible evidence for M3- and M2-dependent components of a motor/sensory system.
BJU international 20070901
-
Pharmacologic management of overactive bladder.
Clinical interventions in aging 20070901
-
Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction.
European urology 20070801
-
Update on drugs for overactive bladder syndrome.
Drug and therapeutics bulletin 20070601
-
M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion.
Cancer research 20070415
-
[Treatment of overactive bladder in elderly and old people].
Der Urologe. Ausg. A 20070401
-
Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
Expert opinion on pharmacotherapy 20070301
-
Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
The Journal of urology 20070201
-
M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors.
Neurourology and urodynamics 20070101
-
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Biological & pharmaceutical bulletin 20070101
-
[Darifenacine--Emselex].
Journal de pharmacie de Belgique 20070101
-
In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
Life sciences 20061214
-
New developments in the treatment of urinary incontinence.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20061201
-
Treatment of overactive bladder in the aging population: focus on darifenacin.
Clinical interventions in aging 20061201
-
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
BJU international 20061101
-
Darifenacin: Pharmacology and clinical usage.
The Urologic clinics of North America 20061101
-
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Naunyn-Schmiedeberg's archives of pharmacology 20061101
-
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
European urology 20060801
-
[Anticholinergics for overactive bladder: does subtype selectivity play a role?].
Der Urologe. Ausg. A 20060701
-
Regulation of bladder muscarinic receptor subtypes by experimental pathologies.
Autonomic & autacoid pharmacology 20060701
-
Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
International urogynecology journal and pelvic floor dysfunction 20060501
-
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
The American journal of medicine 20060301
-
M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.
The Journal of pharmacology and experimental therapeutics 20060201
-
M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder.
The Journal of pharmacology and experimental therapeutics 20060201
-
New drugs 06, part I.
Nursing 20060201
-
Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
International journal of clinical practice 20060101
-
The clinical pharmacokinetics of darifenacin.
Clinical pharmacokinetics 20060101
-
Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
BJU international 20051101
-
Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
European urology 20050901
-
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
World journal of urology 20050901
-
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.
Journal of clinical pharmacology 20050901
-
Solifenacin and darifenacin for overactive bladder.
Obstetrics and gynecology 20050801
-
Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
European urology 20050701
-
Darifenacin in the treatment of overactive bladder.
International journal of clinical practice 20050701
-
Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder.
Naunyn-Schmiedeberg's archives of pharmacology 20050701
-
Darifenacin in the treatment of overactive bladder.
Drugs of today (Barcelona, Spain : 1998) 20050701
-
New treatment options for overactive bladder.
South Dakota journal of medicine 20050601
-
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
BJU international 20050501
-
Increased warning time with darifenacin: a new concept in the management of urinary urgency.
The Journal of urology 20050401
-
Solifenacin and darifenacin for overactive bladder.
The Medical letter on drugs and therapeutics 20050314
-
An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
BJU international 20050301
-
Assessment of cognitive function of the elderly population: effects of darifenacin.
The Journal of urology 20050201
-
New drugs: palifermin, eszopiclone, and darifenacin hydrobromide.
Journal of the American Pharmacists Association : JAPhA 20050101
-
[Overactive bladder].
Krankenpflege Journal 20050101
-
Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats.
World journal of gastroenterology 20041115
-
Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.
Expert opinion on investigational drugs 20041101
-
Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
Current urology reports 20041001
-
Elevating our therapeutic expectations in overactive bladder.
Journal of the American Academy of Nurse Practitioners 20041001
-
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
European journal of pharmacology 20040525
-
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
European urology 20040401
-
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.
British journal of clinical pharmacology 20040201
-
Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Life sciences 20040102
-
Darifenacin: in the treatment of overactive bladder.
Drugs & aging 20040101
-
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability.
British journal of clinical pharmacology 20031201
-
Pharmacological effects of darifenacin on human isolated urinary bladder.
Pharmacology 20031201
-
Update on overactive bladder: pharmacologic approaches on the horizon.
Current urology reports 20031001
-
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Naunyn-Schmiedeberg's archives of pharmacology 20020801
-
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
European journal of pharmacology 19980522
-
Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors.
Journal of receptor and signal transduction research 19970101
